RxDoctor Payments DataLook up a doctor →

Scott Hitchcock, DO

Neurology · Huntsville, ALNPI 1255327557

Payments from drug & device makers

$40,962in general payments, 2019–2025

Across 2,380 payments — averaging $17.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$4K
  • AbbVie$4K
  • Novartis$2K
  • Biogen$2K
  • CSL Behring$2K
  • Pfizer$2K
  • plus $24K from 54 others

What the payments were for

  • Speaking & faculty fees$1950%
  • Food & beverage$40,62899%
  • Education$1390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.279$3,907
AbbVie(2 entities)290$3,902
Novartis151$2,378
Biogen148$2,206
CSL Behring74$2,139
Pfizer103$1,717
EMD Serono, Inc.67$1,162
Neurocrine Biosciences, Inc.60$1,144
Acadia Pharmaceuticals Inc69$1,120
Amgen(2 entities)55$1,085
MDD US Operations, LLC47$1,064
Teva Pharmaceuticals USA, Inc.65$1,029
SK Life Science, Inc.49$1,015
AstraZeneca45$1,013
Lilly USA, LLC59$858
Argenx US, Inc.28$747
Otsuka America Pharmaceutical, Inc.34$724
Supernus Pharmaceuticals, Inc.48$641
Avanir Pharmaceuticals, Inc.36$616
Catalyst Pharmaceuticals, Inc.29$615
Sunovion Pharmaceuticals Inc.42$611
Acorda Therapeutics, Inc32$596
Ipsen Biopharmaceuticals, Inc30$592
Harmony Biosciences LLC22$575
Bristol Myers Squibb28$552
Grifols USA, LLC28$539
Jazz Pharmaceuticals Inc.31$500
Lundbeck LLC28$488
Kyowa Kirin, Inc.28$485
Eisai Inc.32$476
Sanofi23$459
Adamas Pharmaceuticals, Inc.25$456
Johnson & Johnson(2 entities)26$393
Merz Pharmaceuticals, LLC15$378
Genentech USA, Inc.22$362
Biohaven Pharmaceuticals, Inc.13$308
Arbor Pharmaceuticals, Inc.14$304
Impel Pharmaceuticals Inc.15$282
Biohaven Pharmaceutical Holding Company Ltd.13$267
Amneal Pharmaceuticals LLC18$250
TG Therapeutics, Inc.11$237
Cycle Pharmaceuticals Inc11$235
Greenwich Biosciences, Inc.10$212
Sumitomo Pharma America, Inc.10$201
Merck9$162
Axsome Therapeutics, Inc.8$160
Neurelis, Inc.8$150
Takeda Pharmaceuticals U.S.A., Inc.7$137
Impel Pharmaceuticals LLC6$131
Upsher-smith Laboratories LLC7$130
Banner Life Sciences, LLC5$97
Akcea Therapeutics, Inc.4$87
Currax Pharmaceuticals LLC6$85
Aucta Pharmaceuticals, Inc.3$84
ANI Pharmaceuticals, Inc.4$77
Avion Pharmaceuticals5$73
Scilex Pharmaceuticals Inc.4$72
Merz North America, Inc.4$63
Livanova USA, Inc.4$60
Abbott3$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,962 in reported general payments places this provider in the 75th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$559,528
Medicare patients
1,070
Services billed
35,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4648$997,006
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5041$895,539
IngrezzaValbenazine Tosylate38$323,712
Kesimpta PenOfatumumab31$304,197
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$216,935
UbrelvyUbrogepant87$100,647
Nurtec OdtRimegepant Sulfate64$99,596
NuedextaDextromethorphan Hbr/Quinidine43$68,563
GlatopaGlatiramer Acetate12$56,621
Aimovig AutoinjectorErenumab-Aooe70$54,793
BriviactBrivaracetam31$54,515
VimpatLacosamide32$52,195
QuliptaAtogepant38$44,731
FingolimodFingolimod Hcl17$28,388
Sumatriptan Succinate202$26,287

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$2,139$895,53941 claims
Neurocrine Biosciences, Inc.Ingrezza$1,144$323,71238 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$137$216,93525 claims
AbbVieUbrelvy, Qulipta$3,902$145,378125 claims
UCB, Inc.Briviact, Vimpat$3,907$106,71163 claims
PfizerNurtec Odt$1,717$99,59664 claims
Avanir Pharmaceuticals, Inc.Nuedexta$616$68,56343 claims
MerckBelsomra$162$21,99751 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$641$17,51114 claims
Amneal Pharmaceuticals LLCRytary$250$7,99415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 255 neurology providers in Alabama.

Other neurology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →